Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Assets (2016 - 2026)

Neuroone Medical Technologies filings provide 15 years of Assets readings, the most recent being $7.9 million for Q1 2026.

  • On a quarterly basis, Assets rose 76.48% to $7.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $7.9 million, a 76.48% increase, with the full-year FY2025 number at $10.8 million, up 100.85% from a year prior.
  • Assets hit $7.9 million in Q1 2026 for Neuroone Medical Technologies, down from $8.6 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $14.1 million in Q1 2022 to a low of $4.5 million in Q1 2025.
  • Median Assets over the past 5 years was $7.9 million (2026), compared with a mean of $8.2 million.
  • Biggest five-year swings in Assets: crashed 50.24% in 2023 and later surged 120.24% in 2025.
  • Neuroone Medical Technologies' Assets stood at $9.7 million in 2022, then crashed by 39.73% to $5.8 million in 2023, then increased by 11.54% to $6.5 million in 2024, then skyrocketed by 32.08% to $8.6 million in 2025, then decreased by 8.31% to $7.9 million in 2026.
  • The last three reported values for Assets were $7.9 million (Q1 2026), $8.6 million (Q4 2025), and $10.8 million (Q3 2025) per Business Quant data.